susiformavim

Susiformavim is a synthetic, non-steroidal anti-inflammatory drug (NSAID) that is structurally related to the ibuprofen and ketoprofen chemical classes. It is developed by the pharmaceutical company SusPharma and is designed to provide analgesic and anti-inflammatory effects similar to other NSAIDs.

The drug is available in various dosage forms, including tablets and suspensions, to accommodate different patient needs. Susiformavim is typically taken orally and is usually well-tolerated. However, like other NSAIDs, it can cause side effects such as stomach upset, nausea, and gastrointestinal bleeding, particularly at higher doses or in individuals with a history of gastrointestinal issues.

Susiformavim is indicated for the relief of mild to moderate pain and inflammation associated with conditions such as arthritis, muscle pain, and dental procedures. It is not recommended for use in patients with a history of asthma, kidney disease, or liver disease, as it may exacerbate these conditions.

The pharmacokinetics of susiformavim are similar to other NSAIDs, with rapid onset of action and a half-life of approximately 1-2 hours. It is metabolized primarily by the liver, and its active metabolite is excreted primarily by the kidneys.

Susiformavim is not approved for use in all countries, and its availability may vary depending on regional regulations and guidelines. It is important to consult with a healthcare provider before starting any new medication, including susiformavim, to ensure it is appropriate for an individual's specific needs and health status.